GW Pharma

Cambridge, United Kingdom Founded: 1998 • Age: 28 yrs Acquired By Jazz Pharmaceuticals
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy
Annual revenue - Latest available
Total funding $46.5M 3 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products 4 Services tracked
Competitors 11 Brand Intelligence

About GW Pharma

GW Pharma is a company based in Cambridge (United Kingdom) founded in 1998 was acquired by Jazz Pharmaceuticals in February 2021. GW Pharma has raised $46.5 million across 3 funding rounds from investors including Jazz Pharmaceuticals and Mentor Capital. GW Pharma offers products and services including Xywav, Epidiolex, Defitelio, and Rylaze. GW Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, PureTech Health and Biohaven Pharmaceutical, among others.

  • Headquarter Cambridge, United Kingdom
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Gw Pharma Limited
  • Date of Incorporation 29 Jan, 1999
  • Jurisdiction CAMBRIDGE
Operational Areas
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $46.5 M (USD)

    in 3 rounds

  • Latest Funding Round
    $1 M (USD), Post-IPO

    Mar 03, 2017

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Jazz Pharmaceuticals

    (Feb 03, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of GW Pharma

GW Pharma offers a comprehensive portfolio of products and services, including Xywav, Epidiolex, Defitelio, and Rylaze.

Product name locked
Category locked
Primary

Oral solution for treating narcolepsy and idiopathic hypersomnia

Product name locked
Category locked
Locked

Cannabidiol-based treatment for epilepsy seizures

Product name locked
Category locked
Locked

Therapy for preventing complications in leukemia patients

Product name locked
Category locked
Locked

Recombinant treatment for acute lymphoblastic leukemia

People of GW Pharma

Headcount 1000-5000
Employee Profiles 779
Board Members and Advisors 13
Employee Profiles
People
Shelby Reid
Medical Advisor, Oncology
People
Matt Lasmanis
Chief Digital Officer (cdo)
People
Patricia Carr
Senior Vice President, Chief Accounting Officer
People
Luigia de Flaviis
Senior Research Technologist

Unlock access to complete

Board Members and Advisors
people
Jennifer Cook
Director

Unlock access to complete

Funding Insights of GW Pharma

GW Pharma has successfully raised a total of $46.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in GW Pharma

GW Pharma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals and Mentor Capital.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Energy investments and funding for pre-IPO companies in oil, gas, coal, and uranium sectors.
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Premium access

Investor details for GW Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by GW Pharma

Investments
Premium access

Investment portfolio details for GW Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - GW Pharma

Premium access

Detailed financials for GW Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Gw Pharma Comparisons

GW Pharma Primary company
Description
Developer of cannabinoid medicines for MS spasticity, cancer...
Location
Cambridge, United Kingdom
Founded Year
1998
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for GW Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of GW Pharma

GW Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, PureTech Health and Biohaven Pharmaceutical, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Drugs for CNS disorders are developed and advanced.
Locked Locked Locked
Genetically engineered cell therapies are developed for multiple disorders.
Locked Locked Locked
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
Locked Locked Locked
Therapies for neurological and neuropsychiatric diseases are developed.
Locked Locked Locked
Therapies for psychosis and cognitive impairment are developed.
Premium access

Detailed competitors of GW Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Gw Pharma

Premium access

Complete news archive for GW Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GW Pharma

GW Pharma was founded in 1998 and raised its 1st funding round 5 years after it was founded.

GW Pharma is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

GW Pharma is a funded company, having raised a total of $46.5M across 3 funding rounds to date.

GW Pharma was founded in 1998 in Cambridge, United Kingdom, within the pharmaceutical sector. Focus is placed on developing cannabinoid-based treatments, including Sativex for managing spasticity in multiple sclerosis patients and pain in cancer cases, as well as Epidiolex for addressing epilepsy in children. Operations center on research and drug approval processes across Europe and beyond, targeting neurological and pain-related conditions.

GW Pharma's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.

GW Pharma offers Xywav, Epidiolex, Defitelio, and Rylaze.

GW Pharma has 2 investors. Key investors include Jazz Pharmaceuticals, and Mentor Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available